Gilead Sciences

YTD

ALL

Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

CEO

Daniel P. O'Day

CEODaniel P. O'Day

Employees

17,600

Employees17,600

Headquarters

Foster City, California

HeadquartersFoster City, California

Founded

1987

Founded1987

Employees

17,600

Employees17,600

GILD Key Statistics

Market cap

137.53B

Market cap137.53B

Price-Earnings ratio

22.39

Price-Earnings ratio22.39

Dividend yield

2.77%

Dividend yield2.77%

Average volume

7.01M

Average volume7.01M

High today

$114.13

High today$114.13

Low today

$110.16

Low today$110.16

Open price

$113.22

Open price$113.22

Volume

5.46M

Volume5.46M

52 Week high

$121.83

52 Week high$121.83

52 Week low

$81.83

52 Week low$81.83

GILD News

TipRanks 22h

Buy Recommendation for Gilead Sciences Amid Strategic Positioning and Legal Developments

Analyst Terence Flynn from Morgan Stanley maintained a Buy rating on Gilead Sciences and keeping the price target at $143.00. Elevate Your Investing Strategy: T...

Simply Wall St 3d

What Gilead Sciences's Global HIV Partnership and US Manufacturing Expansion Means for Shareholders

In early September 2025, Gilead Sciences announced a partnership with the U.S. State Department and PEPFAR to expand access to its twice-yearly injectable HIV-1...

Simply Wall St 6d

Gilead Sciences Commits To Veeva Systems For Vault CRM Suite

recently announced that Gilead Sciences has committed to using its Veeva Vault CRM, highlighting the company's expansion in the pharmaceutical CRM space through...

Analyst ratings

70%

of 30 ratings

Buy

70%

Hold

30%

Sell

People also own

Based on the portfolios of people who own GILD. This list is generated using Robinhood data, and it’s not a recommendation.

VeriSign

Exelixis

United Therapeutics

Sprouts Farmers Market

Spotify

Franco-Nevada